
    
      The screening period will range from a minimum of 14 days to a maximum of 28 days. The
      Investigators will determine that the subjects meet eligibility criteria and will collect the
      demographic and medical data permitting full characterization of the subject.

      The duration of the randomization period will be 12 weeks. Subjects who meet
      inclusion/exclusion criteria at the Baseline Visit will be randomized to NSI-189 80
      milligrams/day, given as 40 milligrams twice per day, NSI-189 40 milligrams/day, given once a
      day, or placebo. The treatment will be double-blinded.
    
  